logo

Corynebacterium species

Background:

---------------------------------------------------------
Gram-positive bacilli
---------------------------------------------------------
>Corynebacterium species:
     1] Corynebacterium diphtheria
     2] Corynebacterium jeikeium
     3] Corynebacterium urealyticum


Corynebacterium
  • Gram-positive, catalase positive, nonspore-forming, nonmotile, rod-shaped bacteria.
  • Aerobic or facultatively anaerobic.
  • Chemoorganotrophs: 51 - 65% genomic G:C content.
  • Widely distributed in nature and are mostly innocuous.
  • C. diphtheriae: pathogen responsible for diphtheria.
  • Pleomorphic through their life cycles: occur in various lengths and frequently have thickenings at either end, depending on the surrounding conditions.
  • Source: http://en.wikipedia.org/wiki/Corynebacterium
top of page



Therapy:

Important considerations:  The choice of an agent should be based on local antimicrobial sensitivities, site of infection, cost, and comorbid conditions.   Generally, the most common agents/regimens are listed first.   Listed dosages may need to be adjusted for renal dysfunction.   Note: antibiotic therapy and diphtheria antitoxin for severe cases.

Corynebacterium diphtheria:
  1. Erythromycin 500 mg four times daily for 14 days
  2. Penicillin G (25,000 to 50,000 units/kg to a max of 1.2 million units IV q12h until patient can take oral medicine), then Penicillin VK 250 - 500mg orally q6h.   Total treatment course - 14 days
  3. Usually susceptible to multiple other agents:
  4. Clarithromycin 500mg po q12h
  5. Bactrim DS (TMP-SMX) 160/800mg po bid
  6. Ciprofloxacin 250-500 mg orally or 200-400mg IV  q12h.
  7. Vancomycin 1 gram  ivpb q12h (patient-specific dosing required)
  8. Daptomycin 4 - 6 mg/kg IV once daily.  NOT FOR PNEUMONIA
  9. Linezolid 600 mg orally or IV q12h


Corynebacterium jeikeium:  Resistant to many antibiotics, including penicillins, cephalosporins, and aminoglycosides
  1. Vancomycin 1 gram  ivpb q12h (patient-specific dosing required) +/- antipseudomonal aminoglycoside
  2. Daptomycin 4 - 6 mg/kg IV once daily.    - NOT FOR PNEUMONIA
  3. Linezolid 600 mg orally or IV q12h
  4. Tigecycline 100 mg IV x 1, then 50 mg q12h


Corynebacterium urealyticum:  resistant to Beta-lactams, aminoglycosides, and trimethoprim-sulfamethoxazole
  1. Vancomycin 1 gram  ivpb q12h (patient-specific dosing required)
  2. Linezolid 600 mg orally or IV q12h
  3. Daptomycin 4 - 6 mg/kg IV once daily.  NOT FOR PNEUMONIA
  4. Tigecycline 100 mg IV x 1, then 50 mg q12h

Reference(s)


Infectious Disease Section References:

  1. Anand N, Kollef MH. The alphabet soup of pneumonia: CAP, HAP, HCAP, NHAP, and VAP. Semin Respir Crit Care Med. Feb 2009;30(1):3-9.
  2. Arnold FW, LaJoie AS, Brock GN, Peyrani P, Rello J, Menéndez R, et al. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. Arch Intern Med. Sep 14 2009;169(16):1515-24.
  3. Baden LR, Eisenstein BI.Impact of Antibiotic Resistance on the Treatment of Gram-negative Sepsis. Curr Infect Dis Rep. 2000 Oct;2(5):409-416.
  4. Bartlett JG et al. Community-acquired pneumonia in adults: guidelines for management. Guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 1998;26:811-38.
  5. Bartlett JG: Empirical therapy of community-acquired pneumonia: macrolides are not ideal choices. Semin Respir Infect 1997 Dec; 12(4): 329-33
  6. Bartlett JG.1998 Pocket Book of Infectious Disease Therapy., Ninth Edition. Baltimore,MD: Williams&Wikins,1998.
  7. Bernstein JM: Treatment of community-acquired pneumonia--IDSA guidelines. Infectious Diseases Society of America. Chest 1999 Mar; 115(3 Suppl): 9S-13S
  8. Brown SM, Jones BE, Jephson AR, Dean NC. Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia. Crit Care Med. Dec 2009;37(12):3010-6.
  9. CDC. Update to CDC's sexually transmitted diseases treatment guidelines, 2006. fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep. Apr 13 2007;56(14):332-6.
  10. CDC. Centers for Disease Control and Prevention. 2010 STD Treatment Guidelines. http://www.cdc.gov/std/treatment/2010/default.htm
    Accessed: 4-15-2012.
  11. Cunha BA. Antibiotic Essentials 8th.ed. Jones & Bartlett Learning, 2009.
  12. Ewig S et al. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med. 1999;159:1835-42.
  13. Fang WF, Yang KY, Wu CL, Yu CJ, Chen CW, Tu CY, et al. Application and comparison of scoring indices to predict outcomes in patients with healthcare-associated pneumonia. Crit Care. Jan 19 2011;15(1):R32.
  14. File TM Jr. Community-acquired pneumonia: recent guidelines for therapy. J Respir Dis. 1999;20:534-41.
  15. Gilbert DN, Moellering Jr RC, Eliopoulos GM, et al ed. The Sanford Guide to Antimicrobial Therapy, 40th ed. Sperryville, VA: Antimicrobial Therapy; 2010.
  16. Gold HS, Moellering RC. Antimicrobial-drug resistance. N Engl J Med. 1996;335:1445-1453.
  17. Gonzales R, Sande M: What will it take to stop physicians from prescribing antibiotics in acute bronchitis? Lancet 1995 Mar 18; 345(8951): 665-6
  18. Hooton TM, Stamm WE. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am 1997;11:551-581.
  19. Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug Information Handbook. 20th ed. Hudson, OH: Lexi-Comp, Inc; 2011.
  20. Lipsky BA, Berendt AR.Principles and practice of antibiotic therapy of diabetic foot infections. Diabetes Metab Res Rev. 2000 Sep-Oct;16 Suppl 1:S42-6.
  21. Mandell LA , Wunderink RG , Anzueto A , et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults . Clin Infect Dis . 2007;44(suppl 2):S27–S72.
  22. Mufson MA.Pneumococcal Pneumonia. Curr Infect Dis Rep. 1999 Apr;1(1):57-64.
  23. Nabel EG, Federman DD. Infectious Diseases: The Clinician's Guide to Diagnosis, Treatment, and Prevention. Jackson, WY: Teton Data Systems, 2010.
  24. Phua J, See KC, Chan YH, Widjaja LS, Aung NW, Ngerng WJ, et al. Validation and clinical implications of the IDSA/ATS minor criteria for severe community-acquired pneumonia. Thorax. Jul 2009;64(7):598-603.
  25. Pirracchio R, Mateo J, Raskine L, Rigon MR, Lukaszewicz AC, Mebazaa A, et al. Can bacteriological upper airway samples obtained at intensive care unit admission guide empiric antibiotherapy for ventilator-associated pneumonia?. Crit Care Med. Sep 2009;37(9):2559-63.
  26. Reese RE, Betts RF: A Practical Approach to Infectious Diseases. 4th ed. Boston: Little, Brown, and Company; 1996: 251
  27. Runyon B. Ascites and spontaneous bacterial peritonitis. In: Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger & Fordtran's Gastrointestinal and Liver Disease. Vol 2. 8th ed. Philadelphia, Pa: Saunders; 2006:1935-64.
  28. Rybak MJ, Lomaestro BM, Rotschafer JC, et al: Therapeutic monitoring of vancomycin in adults: summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2009; 29:1275-1279.
  29. Stefani SD, Cadore LP, Villaroel RU, Azevedo S, Machado AL. Antibiotic Selection in the Treatment of Febrile Neutropenia: Current Approach and New Directions.
    Braz J Infect Dis. 1998 Jun;2(3):109-117.
  30. Stamm WE, Hooton TM. Management of urinary tract infections in adults. N Engl J Med 1993;329:1328-1334.
  31. Tan J, et al. Expert Guide to Infectious Diseases 2nd ed. Philadelphia: ACP Press/American College of Physicians, 2008.
  32. van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet. Oct 31 2009;374(9700):1543-56.
  33. Wiggins KJ, Craig JC, Johnson DW, Strippoli GF. Treatment for peritoneal dialysis-associated peritonitis. Cochrane Database Syst Rev. Jan 23 2008;CD005284.
  34. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. Dec 17 2010;59:1-110.






Disclaimer

The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.   Read the disclaimer
more Career Center image description
Medical Calculators - A thru Z
Lab Values - A thru Z